Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic ...

Sage Therapeutics (SAGE ... nonbinding proposal it received from Biogen (BIIB) on January 10 to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share.

Shares of Sage Therapeutics Inc. fell more than 20% premarket on Wednesday after a failed trial dealt a blow to the company’s collaboration with Biogen Inc. Sage and Biogen announced Wednesday ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...

Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following a year of significant challenges for the latter. The deal, which values Sage at $7.22 per share, represents ...

On Thursday, Sage Therapeutics Inc. (NASDAQ:SAGE) announced that Biogen Inc (NASDAQ:BIIB) had terminated its rights under the collaboration and license agreement with Sage, which was specific to ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.